세계의 비침습적 산전검사 시장(2025-2035년) : 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측
Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
상품코드:1769901
리서치사:Transparency Market Research
발행일:2025년 05월
페이지 정보:영문 240 Pages
라이선스 & 가격 (부가세 별도)
한글목차
비침습적 산전검사 시장 - 분석 범위
TMR의 조사 보고서 '세계의 비침습적 산전검사 시장'은 2025년부터 2035년까지의 예측 기간 동안 시장 지표에 관한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사했습니다. 2025년을 기준연도, 2035년을 예측연도로 하여 2019년부터 2035년까지 세계의 비침습적 산전검사 시장의 수익과 예측을 제공합니다.
이 보고서는 광범위한 조사를 거쳐 작성되었으며, 1차 조사에서는 분석가가 KOL(Key Opinion Leader), 업계 리더, 의사결정자와의 인터뷰를 실시했습니다.
시장 개황
시장 규모(2024년)
47억 달러
시장 규모(2035년)
132억 달러
CAGR
9.5%
본 보고서에서는 세계의 비침습적 산전검사 시장 경쟁 구도에 대해 분석했습니다.
목차
제1장 서론
제2장 전제조건과 분석방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계의 비침습적 산전검사 시장 분석과 예측(2020-2035년)
제5장 주요 인사이트
기술진보
주요 지역/국가의 규제 상황
가격 동향
Porter's Five Forces 분석
PESTEL 분석
밸류체인 분석
최종사용자를 위한 주요 구매 지표
주요 산업 이벤트(파트너십, 협업, 제품 승인, 합병 및 인수, 자금 조달 및 투자)
경쟁이 제공하는 제품의 벤치마크
제6장 세계 시장의 분석과 예측 : 검사 유형별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 검사 유형별(2020-2035년)
유리 DNA 스크리닝 검사
혈청 마커 스크리닝 검사
신경관 폐쇄 장애 검사
초음파 검사
시장의 매력 : 검사 유형별
제7장 세계 시장의 분석과 예측 : 제품별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 제품별(2020-2035년)
장치
키트 및 시약
시장의 매력 : 제품별
제8장 세계 시장의 분석과 예측 : 기술별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 기술별(2020-2035년)
전체 유전체 서열 분석
SNP 분석
마이크로어레이 분석
롤링 서클 증폭
시장의 매력 : 기술별
제9장 세계 시장의 분석과 예측 : 적응증별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 적응증별(2020-2035년)
다운증후군(21 트리소미)
에드워즈증후군(18 트리소미)
파토증후군(13 트리소미)
터너증후군(모노소미 X/XO)
클라인펠터증후군(XXY)
야곱증후군(XYY)
성별인식
기타(트리플 X 등)
시장의 매력 : 적응증별
제6장 세계 시장 분석 및 예측 : 최종사용자별
소개 및 정의
주요 분석결과/진전
시장 예측(금액 기준) : 최종사용자별(2020-2035년)
병원
전문클리닉
진단실험실
기타(연구기관 등)
시장의 매력 : 최종사용자별
제11장 세계 시장 분석 및 예측 : 지역별
주요 분석결과
시장 예측(금액 기준) : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제12장 북미 시장의 분석과 예측
미국
캐나다
제13장 유럽 시장의 분석과 예측
독일
영국
프랑스
이탈리아
스페인
기타 유럽
제14장 아시아태평양시장의 분석과 예측
중국
인도
일본
호주 및 뉴질랜드
기타 아시아태평양
제15장 라틴아메리카 시장의 분석과 예측
브라질
멕시코
기타 라틴아메리카
제16장 중동 및 아프리카 시장의 분석과 예측
GCC 국가
남아프리카
기타 중동 및 아프리카
제17장 경쟁 구도
시장 기업 및 경쟁 매트릭스(기업의 계층별 및 규모별)
시장 점유율 분석 : 기업별(2024년)
기업 프로파일
F. Hoffmann-La Roche Ltd
Natera, Inc.
Illumina, Inc
PerkinElmer Inc.
Eurofins LifeCodexx AG
IGENOMIX
Pacific Biosciences
BGI
Laboratory Corporation of America Holdings
Agilent Technologies, Inc.
Berry Genetics Inc.
CSM
영문 목차
영문목차
Non-invasive Prenatal Testing Market - Scope of Report
TMR's report on the global non-invasive prenatal testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global non-invasive prenatal testing market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-invasive prenatal testing market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-invasive prenatal testing market.
Market Snapshot
Market Value in 2024
US$ 4.7 Bn
Market Value in 2035
US$ 13.2 Bn
CAGR
9.5%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-invasive prenatal testing market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-invasive prenatal testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-invasive prenatal testing market.
The report delves into the competitive landscape of the global non-invasive prenatal testing market. Key players operating in the global non-invasive prenatal testing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-invasive prenatal testing market profiled in this report.
Key Questions Answered in Global non-invasive prenatal testing Market Report:
What is the sales/revenue generated by non-invasive prenatal testing across all regions during the forecast period?
What are the opportunities in the global non-invasive prenatal testing market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Non-invasive Prenatal Testing Market - Research Objectives and Research Approach
The comprehensive report on the global non-invasive prenatal testing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global non-invasive prenatal testing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-invasive prenatal testing market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Non-invasive Prenatal Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, 2020 to 2035
5. Key Insights
5.1. Technological Advancements
5.2. Pricing Trends
5.3. Regulatory Landscape across Key Regions / Countries
5.4. PORTER's Five Forces Analysis
5.5. PESTEL Analysis
5.6. Value Chain Analysis
5.7. Key Purchase Metrics for End-users
5.8. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
5.9. Benchmarking of the Product Offered by the Competitors
6. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Test Type, 2020 to 2035
6.3.1. Cell-Free DNA Screening Test
6.3.2. Serum Marker Screening Test
6.3.3. Neural Tube Defects Test
6.3.4. Ultrasonography
6.4. Market Attractiveness By Test Type
7. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product, 2020 to 2035
7.3.1. Instruments
7.3.2. Kits & Reagents
7.4. Market Attractiveness By Product
8. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Technology, 2020 to 2035
8.3.1. Whole-Genome Sequencing
8.3.2. SNP Analysis
8.3.3. Microarray Analysis
8.3.4. Rolling Circle Amplification
8.4. Market Attractiveness By Technology
9. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Indication, 2020 to 2035
9.3.1. Down Syndrome (trisomy 21)
9.3.2. Edwards syndrome (trisomy 18)
9.3.3. Patau syndrome (trisomy 13)
9.3.4. Turner Syndrom (Monosomy X/XO)
9.3.5. Klinefelter Syndrome (XXY)
9.3.6. Jacob's Syndrome (XYY)
9.3.7. Gender Identification
9.3.8. Others (Triple X, etc.)
9.4. Market Attractiveness By Indication
10. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By End-user, 2020 to 2035
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.3.3. Diagnostics Laboratories
10.3.4. Others (Research Institutes, etc.)
10.4. Market Attractiveness By End-user
11. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region
12. North America Non-invasive Prenatal Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Test Type, 2020 to 2035
12.2.1. Cell-Free DNA Screening Test
12.2.2. Serum Marker Screening Test
12.2.3. Neural Tube Defects Test
12.2.4. Ultrasonography
12.3. Market Value Forecast By Product, 2020 to 2035
12.3.1. Instruments
12.3.2. Kits & Reagents
12.4. Market Value Forecast By Technology, 2020 to 2035
12.4.1. Whole-Genome Sequencing
12.4.2. SNP Analysis
12.4.3. Microarray Analysis
12.4.4. Rolling Circle Amplification
12.5. Market Value Forecast By Indication, 2020 to 2035
12.5.1. Down Syndrome (trisomy 21)
12.5.2. Edwards syndrome (trisomy 18)
12.5.3. Patau syndrome (trisomy 13)
12.5.4. Turner Syndrom (Monosomy X/XO)
12.5.5. Klinefelter Syndrome (XXY)
12.5.6. Jacob's Syndrome (XYY)
12.5.7. Gender Identification
12.5.8. Others (Triple X, etc.)
12.6. Market Value Forecast By End-user, 2020 to 2035
12.6.1. Hospitals
12.6.2. Specialty Clinics
12.6.3. Diagnostics Laboratories
12.6.4. Others (Research Institutes, etc.)
12.7. Market Value Forecast By Country, 2020 to 2035
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Test Type
12.8.2. By Product
12.8.3. By Technology
12.8.4. By Indication
12.8.5. By End-user
12.8.6. By Country
13. Europe Non-invasive Prenatal Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Test Type, 2020 to 2035
13.2.1. Cell-Free DNA Screening Test
13.2.2. Serum Marker Screening Test
13.2.3. Neural Tube Defects Test
13.2.4. Ultrasonography
13.3. Market Value Forecast By Product, 2020 to 2035
13.3.1. Instruments
13.3.2. Kits & Reagents
13.4. Market Value Forecast By Technology, 2020 to 2035
13.4.1. Whole-Genome Sequencing
13.4.2. SNP Analysis
13.4.3. Microarray Analysis
13.4.4. Rolling Circle Amplification
13.5. Market Value Forecast By Indication, 2020 to 2035
13.5.1. Down Syndrome (trisomy 21)
13.5.2. Edwards syndrome (trisomy 18)
13.5.3. Patau syndrome (trisomy 13)
13.5.4. Turner Syndrom (Monosomy X/XO)
13.5.5. Klinefelter Syndrome (XXY)
13.5.6. Jacob's Syndrome (XYY)
13.5.7. Gender Identification
13.5.8. Others (Triple X, etc.)
13.6. Market Value Forecast By End-user ,2020 to 2035
13.6.1. Hospitals
13.6.2. Specialty Clinics
13.6.3. Diagnostics Laboratories
13.6.4. Others (Research Institutes, etc.)
13.7. Market Value Forecast By Country/Sub-region ,2020 to 2035
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Test Type
13.8.2. By Product
13.8.3. By Technology
13.8.4. By Indication
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Non-invasive Prenatal Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Test Type, 2020 to 2035
14.2.1. Cell-Free DNA Screening Test
14.2.2. Serum Marker Screening Test
14.2.3. Neural Tube Defects Test
14.2.4. Ultrasonography
14.3. Market Value Forecast By Product, 2020 to 2035
14.3.1. Instruments
14.3.2. Kits & Reagents
14.4. Market Value Forecast By Technology, 2020 to 2035
14.4.1. Whole-Genome Sequencing
14.4.2. SNP Analysis
14.4.3. Microarray Analysis
14.4.4. Rolling Circle Amplification
14.5. Market Value Forecast By Indication, 2020 to 2035
14.5.1. Down Syndrome (trisomy 21)
14.5.2. Edwards syndrome (trisomy 18)
14.5.3. Patau syndrome (trisomy 13)
14.5.4. Turner Syndrom (Monosomy X/XO)
14.5.5. Klinefelter Syndrome (XXY)
14.5.6. Jacob's Syndrome (XYY)
14.5.7. Gender Identification
14.5.8. Others (Triple X, etc.)
14.6. Market Value Forecast By End-user, 2020 to 2035
14.6.1. Hospitals
14.6.2. Specialty Clinics
14.6.3. Diagnostics Laboratories
14.6.4. Others (Research Institutes, etc.)
14.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
14.7.1. China
14.7.2. India
14.7.3. Japan
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Test Type
14.8.2. By Product
14.8.3. By Technology
14.8.4. By Indication
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Non-invasive Prenatal Testing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Test Type, 2020 to 2035
15.2.1. Cell-Free DNA Screening Test
15.2.2. Serum Marker Screening Test
15.2.3. Neural Tube Defects Test
15.2.4. Ultrasonography
15.3. Market Value Forecast By Product, 2020 to 2035
15.3.1. Instruments
15.3.2. Kits & Reagents
15.4. Market Value Forecast By Technology ,2020 to 2035
15.4.1. Whole-Genome Sequencing
15.4.2. SNP Analysis
15.4.3. Microarray Analysis
15.4.4. Rolling Circle Amplification
15.5. Market Value Forecast By Indication, 2020 to 2035
15.5.1. Down Syndrome (trisomy 21)
15.5.2. Edwards syndrome (trisomy 18)
15.5.3. Patau syndrome (trisomy 13)
15.5.4. Turner Syndrom (Monosomy X/XO)
15.5.5. Klinefelter Syndrome (XXY)
15.5.6. Jacob's Syndrome (XYY)
15.5.7. Gender Identification
15.5.8. Others (Triple X, etc.)
15.6. Market Value Forecast By End-user, 2020 to 2035
15.6.1. Hospitals
15.6.2. Specialty Clinics
15.6.3. Diagnostics Laboratories
15.6.4. Others (Research Institutes, etc.)
15.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Test Type
15.8.2. By Product
15.8.3. By Technology
15.8.4. By Indication
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Non-invasive Prenatal Testing Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Test Type, 2020 to 2035
16.2.1. Cell-Free DNA Screening Test
16.2.2. Serum Marker Screening Test
16.2.3. Neural Tube Defects Test
16.2.4. Ultrasonography
16.3. Market Value Forecast By Product, 2020 to 2035
16.3.1. Instruments
16.3.2. Kits & Reagents
16.4. Market Value Forecast By Technology, 2020 to 2035
16.4.1. Whole-Genome Sequencing
16.4.2. SNP Analysis
16.4.3. Microarray Analysis
16.4.4. Rolling Circle Amplification
16.5. Market Value Forecast By Indication, 2020 to 2035
16.5.1. Down Syndrome (trisomy 21)
16.5.2. Edwards syndrome (trisomy 18)
16.5.3. Patau syndrome (trisomy 13)
16.5.4. Turner Syndrom (Monosomy X/XO)
16.5.5. Klinefelter Syndrome (XXY)
16.5.6. Jacob's Syndrome (XYY)
16.5.7. Gender Identification
16.5.8. Others (Triple X, etc.)
16.6. Market Value Forecast By End-user, 2020 to 2035
16.6.1. Hospitals
16.6.2. Specialty Clinics
16.6.3. Diagnostics Laboratories
16.6.4. Others (Research Institutes, etc.)
16.7. Market Value Forecast By Country/Sub-region ,2020 to 2035
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Test Type
16.8.2. By Product
16.8.3. By Technology
16.8.4. By Indication
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2024)
17.3. Company Profiles
17.3.1. F. Hoffmann-La Roche Ltd
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Natera, Inc.
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Illumina, Inc
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. PerkinElmer Inc.
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Eurofins LifeCodexx AG
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. IGENOMIX
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. Pacific Biosciences
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. BGI
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Laboratory Corporation of America Holdings
